Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer
TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer

TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer

Clinicaltrials.gov identifier:
NCT02975934

Treatment

Study Contact Information:

Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email  

The study is open and recruiting at sites in CA, FL, GA, HI, MD, NE, NV, NJ, NY, NC, OH, TN, TX, VA.


A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

About the Study

The purpose of Triton3 is to determine how patients with castration-resistant cancer, and an inherited gene mutation or tumor genetic deficiency respond to treatment with the rucaparib () compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.  NOTE: This study is no longer enrolling patients.

 

Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email  

This Study is Open To:

NOTE: This study is no longer enrolling patients.

This Study is Not Open To:

NOTE: This study is no longer enrolling patients.